ReviewAntibody therapeutics2020
Development of bispecific antibodies in China: overview and prospects.
Review in Antibody therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Universal broad-spectrum mucosal vaccine design for human coronaviruses inspired by artificial antibodies.NPJ vaccines · 2026Article
- Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications.MedComm · 2025Review
- Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment.Current protein & peptide science · 2025Review
- Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy.Frontiers in immunology · 2025Article
- Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape.International journal of medical sciences · 2025Review
- Review
- Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.Oncoimmunology · 2024Article
- Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.Journal of hematology & oncology · 2023Review
- A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.Breast cancer research and treatment · 2023Article
- Recent advances in immunotherapy for lung cancer.Cancer innovation · 2023Review
- Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.Frontiers in immunology · 2023Review
- Development of therapeutic antibodies for the treatment of diseases.Molecular biomedicine · 2022Review
- Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.Scientific reports · 2022Article
- [Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.International journal of molecular sciences · 2022Review
- Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.Immune network · 2022Review
- Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell.Frontiers in immunology · 2022Article
- Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody.Antibody therapeutics · 2021Article
- Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.Journal of hematology & oncology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A bispecific antibody (bsAb) can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects. BsAbs have attracted significant scientific attentions and efforts towards their development as drugs for cancers. There are 21 bsAbs currently undergoing clinical trials in China. Here, we review their platform technologies, expression and production, and biological activities and bioassay of these bsAbs, and summarize their structural formats and mechanisms of actions. T-cell redirection and checkpoint inhibition are two main mechanisms of the bsAbs that we discuss in detail. Furthermore, we provide our perspective on the future of bsAb development in China, including CD3-bsAbs for solid tumors and related cytokine release syndromes, expression and chemistry, manufacturing and controls, clinical development, and immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.